![Milind Deshpande](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Milind Deshpande
Chief Executive Officer at
ACHILLION PHARMACEUTICALS, INC.
Net worth: 258 815 $ as of 2026-05-30
Profile
Milind S.
Deshpande was the founder of Hyku Biosciences, Inc., founded in 2021, where the titles held included President, Chief Executive Officer & Director from 2021 to 2024.
Current jobs include President & Chief Executive Officer at Achillion Pharmaceuticals, Inc. starting in 2024; Chairman at Avilar Therapeutics, Inc. since 2021; Director at Clear Creek Bio, Inc. since 2020; Independent Director at Spero Therapeutics, Inc. since 2023; and Venture Partner at RA Capital Management LP (Private Equity) since 2018.
Former jobs include Chief Executive Officer & Director at Achillion Pharmaceuticals, Inc. in 2018; Chief Executive Officer & Director at TRIANA Biomedicines, Inc. from 2019 to 2024; President, Chief Executive Officer & Director at Nayan Therapeutics, Inc. from 2019 to 2022; Associate Director-Lead Discovery at Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 2001; and Faculty Member at Boston University School of Medicine from 1988 to 1991.
Education includes a doctorate from The Ohio University conferred in 1986.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-06-22 | 91,454 ( 0.16% ) | 258 815 $ | 2026-05-30 |
Milind Deshpande active positions
| Companies | Position | Start |
|---|---|---|
| SPERO THERAPEUTICS, INC. | Director/Board Member | 2023-07-31 |
| ACHILLION PHARMACEUTICALS, INC. | Chief Executive Officer | 2024-05-31 |
RA Capital Management LP (Private Equity)
 RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of healthcare and life sciences. It provides financing for pre-seed, seed stage, early stage and growth capital requirements . The firm acts as a lead and co-investor, makes follow-on investments and has a board seat requirement. | Private Equity Investor | 2018-09-30 |
Clear Creek Bio, Inc.
 Clear Creek Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for nucleotide synthesis | Director/Board Member | 2020-08-31 |
Avilar Therapeutics, Inc.
 Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company which develops covalent drugs to treat cancer and other autoimmune diseases | Chairman | 2019-12-31 |
Former positions of Milind Deshpande
| Companies | Position | End |
|---|---|---|
Santi Therapeutics, Inc.
 Santi Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel therapeutics to treat diseases | Chief Executive Officer | 2024-02-29 |
Nayan Therapeutics, Inc.
 Nayan Therapeutics, Inc. BiotechnologyHealth Technology Operates as biotechnology company | Chief Executive Officer | 2022-01-31 |
| ACHILLION PHARMACEUTICALS, INC. | Chief Executive Officer | 2018-05-01 |
Bristol-Myers Squibb Pharmaceutical Research Institute | Corporate Officer/Principal | 2000-12-31 |
Training of Milind Deshpande
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
63
1st degree connections
10
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 10 |
|---|---|
Achillion Pharmaceuticals, Inc.
 Achillion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes treatments for infectious diseases | Health Technology |
The Ohio University
 The Ohio University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bristol-Myers Squibb Pharmaceutical Research Institute | |
Spero Therapeutics, Inc.
 Spero Therapeutics, Inc. BiotechnologyHealth Technology Develops therapies for the treatment of bacterial infections | Health Technology |
Boston University School of Medicine
 Boston University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Clear Creek Bio, Inc.
Clear Creek Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for nucleotide synthesis | Health Technology |
Nayan Therapeutics, Inc.
Nayan Therapeutics, Inc. BiotechnologyHealth Technology Operates as biotechnology company | Health Technology |
RA Capital Management LP (Private Equity)
RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of healthcare and life sciences. It provides financing for pre-seed, seed stage, early stage and growth capital requirements . The firm acts as a lead and co-investor, makes follow-on investments and has a board seat requirement. | Finance |
Santi Therapeutics, Inc.
Santi Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel therapeutics to treat diseases | Health Technology |
Avilar Therapeutics, Inc.
Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company which develops covalent drugs to treat cancer and other autoimmune diseases | Commercial Services |
- Stock Market
- Insiders
- Milind Deshpande
